Dr. Joseph A. Bauer, PhD
Director, Translational Medicine & Diagnostics
Dr. Bauer became one of the youngest Staff Scientists in translational medicine at the Cleveland Clinic's Taussig Cancer Institute, where he was responsible for drug design and the development of novel drugs with an emphasis on targeted drug delivery. His fields of specialization include signal transduction pathways, apoptosis, cobalamin chemistry, molecular biology and the biochemistry of nitric oxide. He has over 20 years of experience in drug discovery and development, and 16 years of experience in cancer medicine. Dr. Bauer has received over $3 M in grant support from the National Institutes of Health (NIH), the National Cancer Institute (NCI) and various other foundations for research pertaining to NO-Cbl. His work has resulted in three United States Patents and over twenty-five foreign patents. He is the author of more than 50 abstracts and manuscripts. He currently serves as an academic editor for the scientific journal PLoS ONE, and is an invited editorial reviewer for the Journal of the National Cancer Institute. He is also a scientific reviewer for the American Association for Cancer Research journals including Molecular Cancer Therapeutics, Cancer Research and Clinical Cancer Research, and for the journals of the American Chemical Society. Dr. Bauer has served as a grant reviewer for the American Cancer Society Research Project Council, and in 2013 was an invited grant reviewer for NIH/NCI. Dr. Bauer also holds a degree in Business Administration from Walsh University.
Access Dr. Bauer's Bibliography from the US National Library of Medicine NIH (PubMed):
Dr. Annette M. Sysel, DVM, MS
Dr. Sysel has over 25 years of experience in both private and academic veterinary medicine. She is the author of more than 15 abstracts, manuscripts and book chapters. Her past research established the method of epidural catheterization for the long-term treatment of hind limb pain in horses, a method which was used in the pain management protocol for 2006 Kentucky Derby winner Barbaro following his catastrophic hind limb fracture in the 2006 Preakness Stakes. In 2012 alone, Dr. Sysel procured grant funding from the American Kennel Club, Winn Feline Foundation and Blue Buffalo Foundation for Cancer Research for NO-Cbl-related research. A provisional patent was filed as a direct result of this research. Dr. Sysel has established a solid working relationship with the FDA's Center for Veterinary Medicine. Additionally, Dr Sysel was instrumental in the submission of the pre-IND package to the FDA for the human-use of NO-Cbl. Dr. Sysel was named the 2015 American HERO Veterinarian by the American Humane Association for her efforts in cancer research.
Access Dr. Sysel's Bibliography from the US National Library of Medicine NIH (PubMed):
Dr. Weisun Rao, JD, PhD
Dr. Weisun Rao is a partner at the law firm of GreenbergTraurig, LLP. Dr. Rao focuses his practice on intellectual property law and business law. He is experienced in developing IP strategies and building and managing IP portfolios for legal and business opportunities in the United States, China and elsewhere in the world. Dr. Rao has experience in the pharmaceutical, biotechnology, nutraceutical, medical device, advanced material and mechanical industries. Dr. Rao is also experienced with due diligence and counter-diligence investigation, negotiating and drafting technology transfer agreements and licensing agreements, and providing patentability, validity, infringement, and freedom-to-operate opinions. Dr. Rao is involved in such business transactions as cross-border mergers and acquisitions. He is particularly experienced in advising non-Chinese clients on legal regulations and business practices in China and advising Chinese businesses interested in entering or expanding in the U.S. market. Dr. Rao’s clients include individuals, large corporations, small or medium enterprises and non-for-profit organizations, from the United States, Asia and the Europe Union.
Dr. Michael J. Dunphy, PhD
Director of Laboratory Operations
Dr. Dunphy is the Chairman of the Division of Math and Sciences and a Professor of Chemistry at Walsh University. He was the former Director of Clinical Toxicology for Accutox Labs,and the former Director of Analytical Toxicology at the Timken Mercy Medical Center. Dr. Dunphy has over 36 years of experience in chromatography and quantitative sciences, as well as 29 years of experience in bio-analytical research.
Dr. Joseph A. Lupica, PhD
Dr. Lupica has over 9 years of experience in cancer medicine, and he spent 6 years as a Research Fellow at the Cleveland Clinic's Lerner Research Institute. His specialization includes 10 years of nitric oxide research and development. He is currently an Assistant Professor of Chemistry at Walsh University.
from left to right, profiles listed below:
Targeted delivery of nitric oxide